Skip to main content
Equibles

Darren Cline

Xenon Pharmaceuticals Inc. (XENE)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Darren Cline

Darren Cline was last confirmed as Board Member at Pliant Therapeutics, Inc. (PLRX) in a filing dated April 22, 2024. Darren Cline was last confirmed as Board Member at Pyxis Oncology, Inc. (PYXS) in a filing dated April 28, 2023. Pliant Therapeutics, Inc. reported in an 8-K filed March 8, 2023 that Darren Cline was appointed director, effective March 6, 2023. The proxy statement of Xenon Pharmaceuticals Inc. reports total compensation of $4,048,214 for Darren Cline in fiscal 2025, including a base salary of $279,659. Darren Cline has spoken on 2 earnings calls across 1 company, most recently for Xenon Pharmaceuticals Inc. on August 6, 2026.

“On the Effective Date, the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Governance Committee"), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.”
Pliant Therapeutics, Inc. Form 8-K, filed March 8, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Xenon Pharmaceuticals Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Xenon Pharmaceuticals Inc. (XENE) $279,659 $4,048,214

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.